drugset / Trial / NCT04676971
Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Preliminarily investigate the safety and efficacy of two doses of hzVSF-v13 + SOC vs. placebo + SOC for the treatment of COVID-19 pneumonia.
Timeline
- Start
- 2020-12-11
- Primary completion
- 2021-08-29
- Completion
- 2021-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Burfiralimab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Burfiralimab | Monoclonal antibody | 200 mg | Intravenous |